Inotiv (NOTV) Projected to Post Earnings on Wednesday

Inotiv (NASDAQ:NOTV) will likely be releasing its earnings data after the market closes on Wednesday, February 5th. Analysts expect Inotiv to post earnings of ($0.32) per share and revenue of $121.83 million for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

Inotiv (NASDAQ:NOTV) last released its earnings results on Tuesday, December 3rd. The company reported ($0.16) earnings per share (EPS) for the quarter. Inotiv had a negative return on equity of 15.86% and a negative net margin of 22.10%. On average, analysts expect Inotiv to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Inotiv Price Performance

NOTV stock opened at $4.43 on Tuesday. The company has a current ratio of 1.37, a quick ratio of 1.22 and a debt-to-equity ratio of 2.29. The company has a market cap of $115.25 million, a PE ratio of -1.06 and a beta of 3.59. The stock has a 50-day moving average price of $4.39 and a two-hundred day moving average price of $2.77. Inotiv has a 12-month low of $1.23 and a 12-month high of $11.42.

Insider Transactions at Inotiv

In other news, Director Michael J. Harrington bought 10,000 shares of the firm’s stock in a transaction on Friday, December 6th. The stock was purchased at an average price of $3.98 per share, for a total transaction of $39,800.00. Following the transaction, the director now owns 37,500 shares in the company, valued at approximately $149,250. This trade represents a 36.36 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Nigel Brown bought 7,500 shares of the business’s stock in a transaction on Tuesday, December 10th. The shares were acquired at an average cost of $4.26 per share, for a total transaction of $31,950.00. Following the purchase, the director now directly owns 65,537 shares in the company, valued at $279,187.62. This represents a 12.92 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders have purchased 71,029 shares of company stock valued at $314,248. Insiders own 7.80% of the company’s stock.

About Inotiv

Inotiv, Inc provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line.